Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Benzoquinone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 2/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CASP1 | P29466 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.57 |
| ▸ | DHODH | Q02127 | 1/20 | 0.57 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.57 |
| ▸ | MIF | P14174 | 1/20 | 0.55 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoquinone SCHEMBL1916998 | 0.86 | ALDH1A1 (0.57) | ALDH1A1TDP1HSD17B10RECQLBCHE | |
| Benzoquinone SCHEMBL31055608 | 0.85 | ALDH1A1 (0.67) | ALDH1A1TDP1HSD17B10RECQLBCHE | |
| Benzoquinone SCHEMBL8966070 | 0.84 | TDP1 (0.80) | ALDH1A1TDP1HSD17B10RECQLBCHE | |
| Benzoquinone SCHEMBL8160581 | 0.82 | MIF (0.46) | ALDH1A1TDP1HSD17B10RECQLBCHE | |
| Benzoquinone SCHEMBL1437638 | 0.82 | MIF (0.46) | ALDH1A1TDP1HSD17B10RECQLBCHE | |
| Benzoquinone SCHEMBL9457254 | 0.81 | TDP1 (0.73) | ALDH1A1TDP1HSD17B10RECQLBCHE | |
| Benzoquinone SCHEMBL5335267 | 0.76 | MAOA (0.80) | ALDH1A1TDP1HSD17B10RECQLBCHE | |
| Benzoquinone SCHEMBL28597092 | 0.76 | ALDH1A1 (0.80) | ALDH1A1TDP1HSD17B10RECQLBCHE | |
| Benzoquinone SCHEMBL18103 | 0.76 | — | — | |
| Benzoquinone SCHEMBL5308519 | 0.76 | ALDH1A1 (1.00) | ALDH1A1TDP1HSD17B10RECQLBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090563-A1 | MELANIN-PRODUCING, METHANE-CONSUMING BACTERIA AND METHODS FOR USING THEM | C1IN CORPORATION (US) | 2026-04-30 | — | — | WO | disclosed |
| CN-117599132-A | Advanced brain-nourishing body-building health-care medicine and preparation method thereof | 王顺祥 | 2024-02-27 | — | — | CN | disclosed |
| CN-114316224-B | Preparation method and application of artificial purulent melanin nano material | 四川大学 | 2022-09-09 | — | — | CN | disclosed |
| CN-114316224-A | Preparation method and application of artificial purulent melanin nano material | 四川大学 | 2022-04-12 | — | — | CN | disclosed |
| EP-3137066-A1 | NITISINONE DOSING REGIMENS FOR THE TREATMENT OF ALKAPTONURIA | Swedish Orphan Biovitrum International AB (SE) | 2017-03-08 | — | — | EP | disclosed |
| US-20170049716-A1 | NITISINONE DOSING REGIMENS FOR THE TREATMENT OF ALKAPTONURIA | SWEDISH ORPHAN BIOVITRUM INTERNATIONAL AB (SE) | 2017-02-23 | — | — | US | disclosed |
| US-20150344404-A1 | PDK4 INHIBITOR AND USE THEREOF | THE KITASATO INSTITUTE (JP) | 2015-12-03 | — | — | US | disclosed |
| WO-2015165972-A1 | NITISINONE DOSING REGIMENS FOR THE TREATMENT OF ALKAPTONURIA | SWEDISH ORPHAN BIOVITRUM INTERNATIONAL AB (SE) | 2015-11-05 | — | — | WO | disclosed |
| EP-2939668-A1 | PDK4 INHIBITOR AND USE THEREOF | The Kitasato Institute (JP) | 2015-11-04 | — | — | EP | disclosed |
| WO-2002053772-A1 | NOVEL BIOSENSOR SYSTEM | GREENOVATION BIOTECH GMBH (DE) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344404-A1 | PDK4 INHIBITOR AND USE THEREOF | PDK4, PDK3, PDK2 | ALDH1A1 119/4885TDP1 1361/4885HSD17B10 32/4885 |
| US-20170049716-A1 | NITISINONE DOSING REGIMENS FOR THE TREATMENT OF ALKAPTONURIA | CYP1B1, NQO1, UGT1A1 | ALDH1A1 62/4885TDP1 334/4885HSD17B10 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.